Hot Topic Sessions to Highlight DIA's 21st Annual Euromeeting

Share Article

The Drug Information Association's (DIA's) 21st Annual EuroMeeting will feature more than 125 sessions in 16 themes and 21 preconference tutorials focusing on issues affecting global drug discovery and development.

DIA Logo

The theme approach was very well received in Barcelona and will be retained in Berlin. Certain refinements around the theme sessions have been identified that will support the quest to have all disciplines interacting at our event

The Drug Information Association's (DIA's) 21st Annual EuroMeeting will feature more than 125 sessions in 16 themes and 21 preconference tutorials focusing on issues affecting global drug discovery and development, including hot topics sessions on:

  •     Regulatory Pharmacovigilance
  •     Telematics
  •     The Pharmaceutical Package
  •     Advanced Therapies
  •     New EMEA Transparency Policy
  •     Pharmaceutical Sector Inquiry
  •     EU Agreement: Administrative Regulatory Simplification
  •     Adaptive Designs
  •     Multinational Clinical Trials
  •     Patient Recruitment
  •     Personalised Medicine
  •     Quality-by-Design
  •     Medical Devices/Drug Combination Products
  •     Biosimilars
  •     Biomarkers
  •     Paediatrics

Global drug development is also a key focus of the 21st Annual EuroMeeting. This year's event will include sessions on issues affecting key regions of the world, including China, Japan, Latin America, Africa, and North America. In addition, speakers from the EMEA, FDA and regulatory agencies throughout Europe will present at the event.

"The theme approach was very well received in Barcelona and will be retained in Berlin. Certain refinements around the theme sessions have been identified that will support the quest to have all disciplines interacting at our event," says Programme Co-chair Susanne Keitel, Director, European Directorate of the Quality of Medicines and Healthcare (EDQM), EU. "The 2009 programme committee has developed a meeting that truly represents the interests of all attendees."

This year's plenary session, "Architecture of the Future Governance System," will feature panelists who will set forth their vision for the next five years. Topics will include the evolution of the European Regulatory Network and the contribution of the National Competent Authorities, changes in pharmacovigilance legislation, market access and what Member States will pay for new products, and the impact of counterfeit medicines. Panelists will include:

  •     Christina R. Åkerman, Director General, Medical Products Agency, Sweden
  •     Daan J. A. Crommelin, Scientific Director, Top Institute Pharma - TI Pharma, Netherlands
  •     Alastair Kent, Director, Genetic Interest Group, and President EGAN, UK and EU
  •     Thomas Lönngren, Executive Director, EMEA, EU
  •     Martin Terberger, Head of Unit, European Commission, Enterprise and Industry DG Pharmaceutical Unit, EU
  •     Lisette Tiddens-Engwirda, Secretary General, Standing Committee of European Doctors, EU
  •     Floortje van Nooten, Senior Research Associate - Health Economics, Health Care Analytics Group, United BioSource Corporation, Belgium

The German Satellite Session, "The Marketing Authorisation and Supervision of Medicinal Products and Patients, Doctors and Industry Expectations," will discuss the tasks, duties and cooperation of the regulatory agencies in Germany, the Federal Institute for Drugs and Medical Devices and the Paul-Ehrlich-Institut, in a changing scientific environment. This session will be co-chaired by Birka Lehmann, Director and Professor, Head of Licencing Division 3, BfArMm and Christian Schneider, Acting Head, Division EU Cooperation/Microbiology and Acting Head, Section EU Cooperation Biomedicinal Products, Paul-Ehrlich-Institut. Other presenters will include:

  •     Harald Enzmann, Director and Professor, Head of Licencing Division 2, BfArM
  •     Klaus Cichutek, Vice- President and Professor, Department of Medical, Biotechnology,Paul-Ehrlich-Institut
  •     Karl Broich: Director and Professor, Head of Licencing Division 4, BfArM
  •     Dirk Mentzer, Head, Department of Pharmacoviglance 1, Paul-Ehrlich-Institut
  •     Klaus Cichutek, Vice- President and Professor, Head, Department of Medical Biotechnology, Paul-Ehrlich-Institut
  •     Brigitte Keller-Stanislawski, Director and Professor, Head of Department, Safety of Medicinal Products and Medicinal Devices, Paul-Ehrlich-Institut
  •     Ulrich Hagemann, Director and Professor, Head of Department Safety of Medicinal Products and Medicinal Devices, BfArM

About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA (USA), and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit http://www.diahome.org or call 215-442-6100.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joe Krasowski
Visit website

Media